41 64

Cited 0 times in

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus

DC FieldValueLanguage
dc.contributor.author강은석-
dc.contributor.author이민영-
dc.contributor.author이병완-
dc.contributor.author이용호-
dc.contributor.author차봉수-
dc.date.accessioned2020-12-01T17:53:55Z-
dc.date.available2020-12-01T17:53:55Z-
dc.date.issued2020-11-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180501-
dc.description.abstractIntroduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely prescribed for type 2 diabetes (T2D) and their glycemic control effects are well studied. However, information regarding the effects of switching DPP-4 inhibitors is limited, especially in older patients. Research design and methods: We investigated whether switching from linagliptin to teneligliptin decreases blood glucose in older (≥65 years) T2D patients. In total, 164 patients with T2D who switched from linagliptin to teneligliptin for >12 weeks were included and the primary outcome was glycemic changes. Results: Switching from linagliptin to teneligliptin ameliorated fasting blood glucose (148.1 ± 47.1 to 139.6 ± 43.4 mg/dL), glycated hemoglobin (HbA1c; 7.9 ± 1.3 to 7.5 ± 1.2%), and postprandial blood glucose (224.8 ± 77.4 to 205.8 ± 70.8 mg/dL) levels (all P < 0.05). Low-density lipoprotein cholesterol concentration was reduced while liver and kidney functions were maintained. Subgroup analysis showed that glucose control improved more in patients with uncontrolled hyperglycemia (HbA1c > 8.0%) and chronic kidney disease (estimated glomerular filtration rate <90 mL/min/1.73m2). Multiple logistic analysis indicated higher baseline HbA1c was the strongest predictor of teneligliptin switching response. Conclusion: Switching from linagliptin to teneligliptin helps maintain kidney function and reduce blood glucose safely in older patients with T2D.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherDove Medical Press-
dc.relation.isPartOfDIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleEffect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorEugene Han-
dc.contributor.googleauthorMinyoung Lee-
dc.contributor.googleauthorYong-Ho Lee-
dc.contributor.googleauthorHye Soon Kim-
dc.contributor.googleauthorByung-Wan Lee-
dc.contributor.googleauthorBong-Soo Cha-
dc.contributor.googleauthorEun Seok Kang-
dc.identifier.doi10.2147/DMSO.S267994-
dc.contributor.localIdA00068-
dc.contributor.localIdA05491-
dc.contributor.localIdA05491-
dc.contributor.localIdA02796-
dc.contributor.localIdA02796-
dc.contributor.localIdA02989-
dc.contributor.localIdA02989-
dc.contributor.localIdA03996-
dc.contributor.localIdA03996-
dc.relation.journalcodeJ03921-
dc.identifier.eissn1178-7007-
dc.identifier.pmid33173319-
dc.subject.keywordchronic kidney disease-
dc.subject.keyworddipeptidyl peptidase 4 inhibitor-
dc.subject.keywordlinagliptin-
dc.subject.keywordolder patients-
dc.subject.keywordteneligliptin-
dc.subject.keywordtype 2 diabetes mellitus-
dc.contributor.alternativeNameKang, Eun Seok-
dc.contributor.affiliatedAuthor강은석-
dc.contributor.affiliatedAuthor이민영-
dc.contributor.affiliatedAuthor이민영-
dc.contributor.affiliatedAuthor이병완-
dc.contributor.affiliatedAuthor이병완-
dc.contributor.affiliatedAuthor이용호-
dc.contributor.affiliatedAuthor이용호-
dc.contributor.affiliatedAuthor차봉수-
dc.contributor.affiliatedAuthor차봉수-
dc.citation.number11-
dc.citation.startPage4113-
dc.citation.endPage4121-
dc.identifier.bibliographicCitationDIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, (11) : 4113-4121, 2020-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.